MedPath

ong-term study of TA-650 in patients with psoriasis

Phase 3
Conditions
Psoriasis
Registration Number
JPRN-jRCT2080220314
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

[Inclusion criteria]
Psoriasis patients who are candidates for phototherapy or systemic therapy, 16 years and above, male and female.
[Exclusion criteria]
Patients who, have previously used any anti-TNFalpha therapy, have a history of serious infection which caused hospitalization within 6 months before the registration, have an active tuberculosis, have a complication or a history of malignancy within 5 years before the registration.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy (clinical response), Safety and Pharmacokinetics
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath